ACTG 5178

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是一项II期、开放标签、两组、长期维持治疗研究。该试验旨在研究聚乙二醇干扰素α -2a （PEG-IFN）的长期维持是否会降低HCV/HIV合并感染患者的肝纤维化进展率，这些患者在接受PEG-IFN加利巴韦林治疗期间未能达到或维持低于检测极限的HCV负荷。HCV治疗组和既往治疗组均将纳入研究对象。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase II, open-label, two-arm, long-term maintenance therapy study. This trial is designed to study whether long-term maintenance with pegylated-interferon alfa-2a (PEG-IFN) reduces the rate of liver fibrosis progression in subjects with HCV/HIV co-infection who have failed to achieve or maintain HCV loads below the limit of detection during treatment with PEG-IFN plus ribavirin. Both HCV treatment na¿¿ve and previously treated subjects will be enrolled.